- GlucoTrack is developing a **fully implantable continuous blood glucose monitor (CGM)** designed to last **three years** and measure glucose directly in the blood, differentiating it from current wearable CGM technologies by offering no on-body wearable and overcoming lag time in critical glucose changes.  **[1506983_2145765_0]** **[1506983_2145765_4]** **[1506983_2145765_6]** 
- The company completed a first-in-human OUS study safely earlier this year and is starting another OUS study in Australia in **Q3 2025**.  **[1506983_2145765_0]** **[1506983_2145765_5]** **[1506983_2145765_6]** 
- GlucoTrack is engaged with the FDA for an Investigational Device Exemption (IDE) study in the U.S., targeting approval by the **end of 2025** and trial initiation in **Q1 2026**.  **[1506983_2145765_0]** **[1506983_2145765_5]** **[1506983_2145765_6]** 
- The total addressable market for their device is **10.7 million** patients, with an estimated serviceable market of approximately **3 million** patients who would likely consider an implantable CGM.  **[1506983_2145765_6]** 
- GlucoTrack anticipates potential commercial approval in later **2028**, with an estimated capital requirement of **$60 million to $75 million** to reach this milestone.  **[1506983_2145765_5]** **[1506983_2145765_7]**

GlucoTrack provides update on implantable CGM development and market strategy

- Glucotrack, Inc. (GCTK) entered into a Purchase Agreement with Sixth Borough Capital Fund, LP on **September 11, 2025**, under which the Investor committed to purchase up to **$20.0 million** of the Company's common stock over a **24-month period**.  **[1506983_0001493152-25-013094_ex10-1.htm:0]** **[1506983_0001493152-25-013094_form8-k.htm:1]** **[1506983_0001493152-25-013094_ex10-1.htm:67]** 
- The Company has the discretion to sell shares, with "Regular Purchases" limited to **20,000 shares** (potentially increasing to **30,000 shares** if the stock price is not less than **$5.00**) and the Investor's obligation per purchase capped at **$500,000**.  **[1506983_0001493152-25-013094_form8-k.htm:1]** **[1506983_0001493152-25-013094_ex10-1.htm:6]** 
- A commitment fee of **1.5%** of the total commitment amount is payable to the Investor, and the total shares sold are subject to an "Exchange Cap" of **179,792 shares** (19.99% of pre-agreement outstanding shares) unless stockholder approval is obtained or certain price conditions are met.  **[1506983_0001493152-25-013094_form8-k.htm:4]** **[1506983_0001493152-25-013094_ex10-1.htm:67]** 
- The agreement restricts the Company from entering into variable, reset, or adjustable equity or equity-linked transactions without Investor approval, with an exception for a future at-the-market offering facility with Dawson James Securities, Inc..  **[1506983_0001493152-25-013094_form8-k.htm:4]** **[1506983_0001493152-25-013094_ex10-1.htm:41]**

Glucotrack (GCTK)